Five of the nine studies reported various adverse events associated with SGLT2 inhibitor use, including DKA, sepsis, urinary tract infection, genital infection, arrhythmia, hypoglycemia, amputation, and fournier’s gangrene. Here, SLC5A2 is linked to Hypoglycemia.